Medicine and Dentistry
Malignant Neoplasm
100%
Neoplasm
91%
Overall Survival
79%
Diseases
64%
Breast Cancer
59%
Radiation Therapy
30%
Progression Free Survival
30%
Biological Marker
30%
Clinical Trial
29%
Recurrent Disease
29%
Cancer
28%
Prostate Cancer
27%
Metastatic Carcinoma
25%
Lung Cancer
23%
Non Small Cell Lung Cancer
23%
Acute Myeloid Leukemia
21%
Hazard Ratio
21%
Surgery
20%
Arm
18%
Biopsy Technique
18%
Melanoma
17%
Magnetic Resonance Imaging
15%
Oncology
14%
Prognostic Factor
14%
Multivariate Analysis
14%
Systemic Therapy
14%
Immunity
14%
Odds Ratio
13%
Recurrence Free Survival
13%
Chemoradiotherapy
13%
Neoadjuvant Chemotherapy
13%
Survival Rate
12%
Ovarian Cancer
12%
Adverse Event
12%
Myelodysplastic Syndrome
12%
Targeted Therapy
12%
Triple Negative Breast Cancer
12%
Computer Assisted Tomography
11%
Pancreas Cancer
11%
Retrospective Study
11%
Immunotherapy
11%
Proportional Hazards Model
11%
Symptomatic Treatment
11%
Diagnosis
10%
Adenocarcinoma
10%
Lung
10%
Quality of Life
10%
Phase II Trials
10%
Neck
10%
Lymph Node
10%
Advanced Cancer
10%
Ganglioglioma
10%
Meta-Analysis
9%
Hepatocellular Carcinoma
9%
Glioblastoma
9%
Head and Neck Cancer
9%
Primary Tumor
9%
Epidermal Growth Factor Receptor
9%
Minimal Residual Disease
9%
Squamous Cell Carcinoma
9%
B-Cell Chronic Lymphocytic Leukemia
9%
Immune Checkpoint Inhibitor
9%
Multiple Myeloma
8%
Pancreas Adenocarcinoma
8%
Logistic Regression Analysis
8%
Cancer Therapy
8%
Cervical Cancer
8%
Prevalence
8%
Immunohistochemistry
8%
Randomized Controlled Trial
8%
Health Care Cost
8%
Uterine Cancer
8%
Rituximab
8%
Disease Free Survival
8%
Clear Cell Renal Cell Carcinoma
8%
Adolescence
8%
Doxorubicin
7%
T Cell
7%
Paclitaxel
7%
Estrogen Receptor
7%
Body Mass Index
7%
Cancer Diagnosis
7%
Colorectal Carcinoma
7%
Brain Metastasis
7%
Acute Lymphoblastic Leukemia
7%
Cancer Cell
7%
Intensity Modulated Radiation Therapy
7%
Cyclophosphamide
7%
Wart Virus
6%
Carcinoma
6%
Systematic Review
6%
Metastatic Breast Cancer
6%
Neoadjuvant Therapy
6%
Gene Expression
6%
Outpatient
6%
Patient Referral
6%
Chronic Pancreatitis
6%
Drug Megadose
6%
Distant Metastasis
6%
Cohort Analysis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
85%
Neoplasm
61%
Overall Survival
59%
Diseases
52%
Clinical Trial
45%
Chemotherapy
44%
Breast Cancer
32%
Progression Free Survival
31%
Biological Marker
27%
Acute Myeloid Leukemia
25%
Prostate Cancer
21%
Non Small Cell Lung Cancer
20%
Lung Cancer
20%
Recurrent Disease
17%
Adverse Event
16%
Phase II Trials
16%
Remission
15%
Myelodysplastic Syndrome
14%
Immunotherapy
14%
Paclitaxel
13%
Maximum Tolerated Dose
12%
Glioblastoma
11%
Solid Malignant Neoplasm
11%
Chemoradiation Therapy
11%
Cyclophosphamide
11%
Chronic Lymphatic Leukemia
10%
Recurrence Free Survival
10%
Advanced Cancer
10%
Survival Rate
9%
Phase I Trials
9%
Epidermal Growth Factor Receptor
9%
Pancreas Cancer
9%
Fludarabine
9%
Liver Cell Carcinoma
8%
Rituximab
8%
Melanoma
8%
Doxorubicin
7%
Bevacizumab
7%
Squamous Cell Carcinoma
7%
Cytarabine
7%
Multiple Myeloma
7%
Adenocarcinoma
7%
Combination Therapy
7%
Acute Lymphoblastic Leukemia
7%
Immune Checkpoint Inhibitor
7%
Ovary Cancer
6%
Metastatic Breast Cancer
6%
Venetoclax
6%
Leukemia
6%
Clinical Trial Design
6%
Protein P53
6%
Gemcitabine
6%
Metastasis
6%
Minimal Residual Disease
6%
Busulfan
6%
Drug Development
6%
Dexamethasone
5%
Renal Cell Carcinoma
5%
Lenalidomide
5%
Retrospective Study
5%
Triple Negative Breast Cancer
5%
Placebo
5%
Protein Tyrosine Kinase Inhibitor
5%
Cisplatin
5%
Disease Exacerbation
5%
Head and Neck Cancer
5%
Survival Time
5%
Colorectal Carcinoma
5%
Disease Free Survival
5%
Tumor Growth
5%
Prevalence
5%
Cohort Study
5%
Erlotinib
5%
Keyphrases
Overall Survival
57%
Tumor
34%
Confidence Interval
33%
Phase II Trial
23%
Progression-free Survival
22%
Acute Myeloid Leukemia
22%
Phase II Study
21%
Chemotherapy
20%
Non-small Cell Lung Cancer (NSCLC)
20%
Hazard Ratio
18%
Breast Cancer
18%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
17%
Clinical Outcomes
15%
Cancer Patients
15%
Clinical Trials
14%
High Risk
14%
Median Overall Survival
13%
MD Anderson Cancer Center
13%
Prostate Cancer
12%
Pathological Complete Response
12%
Multivariate Analysis
12%
In Cancer
11%
Relapsed or Refractory
11%
Lung Cancer
11%
Chronic Lymphocytic Leukemia
10%
Newly Diagnosed
10%
Triple-negative Breast Cancer
10%
Prognostic Factors
10%
Neoadjuvant Chemotherapy
9%
Odds Ratio
9%
Survival Outcomes
9%
Myelodysplastic Syndrome
9%
Recurrence-free Survival
9%
Partial Response
9%
Complete Remission
9%
Neoadjuvant
9%
Melanoma
9%
Programmed Death-ligand 1 (PD-L1)
8%
Cyclophosphamide
8%
Chronic Myeloid Leukemia
8%
Radiotherapy
8%
Complete Response
8%
Immune Checkpoint Inhibitors
8%
Radiation Therapy
8%
Rituximab
8%
Patients with Cancer
8%
Adverse Events
8%
Response Rate
7%
Phase I Trial
7%
Metastasis
7%
Targeted Therapy
7%
Glioblastoma
7%
Paclitaxel
7%
Human Epidermal Growth Factor Receptor 2 (HER2)
7%
Fludarabine
7%
Breast Cancer Patients
7%
Meta-analysis
7%
Metastatic Breast Cancer
7%
Venetoclax
7%
Median Progression-free Survival
7%
Stable Disease
7%
Bevacizumab
7%
Patients with Advanced Cancer
7%
Head-and-neck Cancer
7%
Single Center
7%
Single Institution
6%
Risk Factors
6%
Multiple Myeloma
6%
Head-and-neck
6%
Doxorubicin
6%
Long-term Survival
6%
Simulation Study
6%
Hepatocellular Carcinoma
6%
Overall Response Rate
6%
Patient Survival
6%
Phase II Clinical Trial
6%
Multivariable
6%
Randomized Phase II Trial
6%
Disease Progression
6%
Inflammatory Breast Cancer
5%
Nivolumab
5%
Maximum Tolerated Dose
5%
Disease-free Survival
5%
Systemic Therapy
5%
University of Texas
5%
Older Patients
5%
Metastatic Melanoma
5%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
5%
Glioma
5%
Immunohistochemistry
5%
Minimal Residual Disease
5%
Overexpression
5%
Resection
5%
Malignancy
5%
Randomized Trial
5%
Ovarian Cancer
5%
Tumor Protein p53 (TP53)
5%
Center Experience
5%
Primary Tumor
5%
Randomized Clinical Trial
5%